TORRENT-LEVETIRACETAM TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

LEVETIRACETAM

থেকে পাওয়া:

TORRENT PHARMACEUTICALS LIMITED

এটিসি কোড:

N03AX14

INN (আন্তর্জাতিক নাম):

LEVETIRACETAM

ডোজ:

750MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

LEVETIRACETAM 750MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100/120

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

MISCELLANEOUS ANTICONVULSANTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0148843003; AHFS:

অনুমোদন অবস্থা:

CANCELLED (UNRETURNED ANNUAL)

অনুমোদন তারিখ:

2021-12-20

পণ্য বৈশিষ্ট্য

_ _
_ _
_Page 1 of 32_
PRODUCT MONOGRAPH
PR
TORRENT-LEVETIRACETAM
Levetiracetam Tablets USP
250 mg, 500 mg and 750 mg
Antiepileptic Agent
Torrent Pharmaceuticals Ltd.
Indrad – 382 721,
Dist. Mehsana
India
Control # 181391
Date of Revision:
January 26, 2015
_ _
_ _
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................15
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL INFORMATION
..........................................................................19
CLINICAL TRIALS
..........................................................................................................20
DETAILED PHARMACOLOGY
..........................................................................